PPIDT00047

Drug Information
NameAbciximab
SequenceEVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVYMELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH
DrugBank_IDDB00054
Typebiotech
IndicationAbciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.
Dosage Forms
Form Route Strength
Injection, solution Intravenous
10 mg/5ml
Injection, solution Intravenous
2 mg/1mL
Solution Intravenous
2 mg / mL
Solution Parenteral
10.000 mg
Solution Parenteral
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P05106 ITGB3 Integrin beta-3 Homo sapiens antagonist Link
target P08514 ITGA2B Integrin alpha-IIb Homo sapiens antagonist Link
target P12318 FCGR2A Low affinity immunoglobulin gamma Fc region receptor II-a Homo sapiens unknown Link
target P31994 FCGR2B Low affinity immunoglobulin gamma Fc region receptor II-b Homo sapiens unknown Link
target P04004 VTN Vitronectin Homo sapiens unknown Link